RATIONALE: Mitragyna speciosa (kratom) may hold promise as both an analgesic and treatment for opioid use disorder. Mitragynine, its primary alkaloid constituent, is an opioid receptor ligand. However, the extent to which the in vivo effects of mitragynine are mediated by opioid receptors, or whether mitragynine interacts with other opioid agonists, is not fully established. OBJECTIVES: The effects of mitragynine and the prototypical opioid agonist morphine were compared for their capacity to decrease operant responding for food delivery, and to increase response latency to a thermal stimulus. METHODS: Male and female Sprague-Dawley rats responded under a multiple cycle fixed ratio 10 schedule of food delivery and were tested on a hot plate (52 °C) immediately after each cycle. Morphine and mitragynine were administered alone, in combination with each other, and in combination with the opioid antagonist naltrexone. RESULTS: Morphine and mitragynine dose-dependently decreased schedule-controlled responding; the ED50 values were 7.3 and 31.5 mg/kg, respectively. Both drugs increased thermal antinociception; the ED50 value for morphine was 18.3. Further, doses of naltrexone that antagonized morphine did not antagonize mitragynine. Mitragynine (17.8 mg/kg) did not alter the rate-decreasing or antinociceptive effects of morphine. CONCLUSIONS: The antinociceptive effects of mitragynine and morphine occur at doses larger than those that disrupt learned behavior. Opioid receptors do not appear to mediate the disruptive effects of mitragynine on learned behavior. Mitragynine had lesser antinociceptive effects than morphine, and these did not appear to be mediated by opioid receptors. The pharmacology of mitragynine includes a substantial non-opioid mechanism.
RATIONALE: Mitragyna speciosa (kratom) may hold promise as both an analgesic and treatment for opioid use disorder. Mitragynine, its primary alkaloid constituent, is an opioid receptor ligand. However, the extent to which the in vivo effects of mitragynine are mediated by opioid receptors, or whether mitragynine interacts with other opioid agonists, is not fully established. OBJECTIVES: The effects of mitragynine and the prototypical opioid agonist morphine were compared for their capacity to decrease operant responding for food delivery, and to increase response latency to a thermal stimulus. METHODS: Male and female Sprague-Dawley rats responded under a multiple cycle fixed ratio 10 schedule of food delivery and were tested on a hot plate (52 °C) immediately after each cycle. Morphine and mitragynine were administered alone, in combination with each other, and in combination with the opioid antagonist naltrexone. RESULTS:Morphine and mitragynine dose-dependently decreased schedule-controlled responding; the ED50 values were 7.3 and 31.5 mg/kg, respectively. Both drugs increased thermal antinociception; the ED50 value for morphine was 18.3. Further, doses of naltrexone that antagonized morphine did not antagonize mitragynine. Mitragynine (17.8 mg/kg) did not alter the rate-decreasing or antinociceptive effects of morphine. CONCLUSIONS: The antinociceptive effects of mitragynine and morphine occur at doses larger than those that disrupt learned behavior. Opioid receptors do not appear to mediate the disruptive effects of mitragynine on learned behavior. Mitragynine had lesser antinociceptive effects than morphine, and these did not appear to be mediated by opioid receptors. The pharmacology of mitragynine includes a substantial non-opioid mechanism.
Entities:
Keywords:
Analgesia; Hot plate; Kratom; Opioid; Pain; Rodent
Authors: Soumen Chakraborty; Rajendra Uprety; Samuel T Slocum; Takeshi Irie; Valerie Le Rouzic; Xiaohai Li; Lisa L Wilson; Brittany Scouller; Amy F Alder; Andrew C Kruegel; Michael Ansonoff; Andras Varadi; Shainnel O Eans; Amanda Hunkele; Abdullah Allaoa; Sanjay Kalra; Jin Xu; Ying Xian Pan; John Pintar; Bronwyn M Kivell; Gavril W Pasternak; Michael D Cameron; Jay P McLaughlin; Dalibor Sames; Susruta Majumdar Journal: J Med Chem Date: 2021-11-16 Impact factor: 7.446
Authors: Erin C Berthold; Shyam H Kamble; Kanumuri S Raju; Michelle A Kuntz; Alexandria S Senetra; Marco Mottinelli; Francisco León; Luis F Restrepo; Avi Patel; Nicholas P Ho; Takato Hiranita; Abhisheak Sharma; Lance R McMahon; Christopher R McCurdy Journal: Drug Metab Dispos Date: 2021-11-10 Impact factor: 3.922
Authors: Francisco León; Samuel Obeng; Marco Mottinelli; Yiming Chen; Tamara I King; Erin C Berthold; Shyam H Kamble; Luis F Restrepo; Avi Patel; Lea R Gamez-Jimenez; Carolina Lopera-Londoño; Takato Hiranita; Abhisheak Sharma; Aidan J Hampson; Clinton E Canal; Lance R McMahon; Christopher R McCurdy Journal: J Med Chem Date: 2021-09-01 Impact factor: 8.039
Authors: Samuel Obeng; Shyam H Kamble; Morgan E Reeves; Luis F Restrepo; Avi Patel; Mira Behnke; Nelson J-Y Chear; Surash Ramanathan; Abhisheak Sharma; Francisco León; Takato Hiranita; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy Journal: J Med Chem Date: 2019-12-27 Impact factor: 7.446
Authors: A N Baldwin; M L Banks; S A Marsh; E A Townsend; M Venniro; Y Shaham; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2022-01-19 Impact factor: 4.530
Authors: Soumen Chakraborty; Jeffrey F DiBerto; Abdelfattah Faouzi; Sarah M Bernhard; Anna M Gutridge; Steven Ramsey; Yuchen Zhou; Davide Provasi; Nitin Nuthikattu; Rahul Jilakara; Melissa N F Nelson; Wesley B Asher; Shainnel O Eans; Lisa L Wilson; Satyanarayana M Chintala; Marta Filizola; Richard M van Rijn; Elyssa B Margolis; Bryan L Roth; Jay P McLaughlin; Tao Che; Dalibor Sames; Jonathan A Javitch; Susruta Majumdar Journal: J Med Chem Date: 2021-09-10 Impact factor: 8.039
Authors: Samuel Obeng; Jenny L Wilkerson; Francisco León; Morgan E Reeves; Luis F Restrepo; Lea R Gamez-Jimenez; Avi Patel; Anna E Pennington; Victoria A Taylor; Nicholas P Ho; Tobias Braun; John D Fortner; Morgan L Crowley; Morgan R Williamson; Victoria L C Pallares; Marco Mottinelli; Carolina Lopera-Londoño; Christopher R McCurdy; Lance R McMahon; Takato Hiranita Journal: J Pharmacol Exp Ther Date: 2020-12-31 Impact factor: 4.030